Why RenovoRx Stock Is Trading Higher Today

RenovoRx RNXT shares are trading higher after the company was granted FDA clearance for 'Catheter, Intravascular Occluding, Temporary.'

RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.

At last check, RenovoRx was trading 102.4% higher at $15.61 per share. The stock has a 52-week high of $16.43 and a 52-week low $6.66.